샘플 요청 목록

 카트 문의
시장보고서
상품코드
2067595

조직 진단 시장 규모, 점유율 및 동향 분석 보고서 : 기술별, 용도별, 검사 법별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Tissue Diagnostics Market Size, Share & Trends Analysis Report By Technology, By Application, By Modality, By End Use, By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: 구분자 Grand View Research | 페이지 정보: 영문 171 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




가격
Unprintable PDF & Excel (Single User License) help
보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.
US $ 5,950 금액 안내 화살표 ￦ 9,263,000
Printable PDF & Excel (5-User License) help
보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.
US $ 6,950 금액 안내 화살표 ￦ 10,820,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.
US $ 8,950 금액 안내 화살표 ￦ 13,934,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

조직 진단 시장 개요

세계의 조직 진단 시장 규모는 2025년에 93억 7,000만 달러로 평가되며, 2033년에 185억 8,000만 달러에 달할 것으로 예측됩니다.

2026-2033년 연평균 성장률(CAGR) 9.11%로 성장할 것으로 전망됩니다. 전 세계 암 부담의 증가가 시장 성장을 주도하고 있으며, 정밀 종양학의 보급이 확대되고 있는 점과 조직 기반 진단 기술의 지속적인 발전도 주요 요인으로 작용하고 있습니다.

자주 묻는 질문

  • 조직 진단 시장의 규모는 어떻게 변할 것으로 예상되나요?
  • 조직 진단 시장의 성장 요인은 무엇인가요?
  • 조직 진단 시장의 연평균 성장률(CAGR)은 어떻게 되나요?

목차

제1장 조사 방법과 범위

제2장 개요

제3장 시장 : 변수, 동향, 범위

제4장 기술별 비즈니스 분석

제5장 용도별 비즈니스 분석

제6장 검사 법별 비즈니스 분석

제7장 최종 용도별 비즈니스 분석

제8장 지역별 비즈니스 분석

제9장 경쟁 구도

KSA

Tissue Diagnostics Market Summary

The global tissue diagnostics market size was valued at USD 9.37 billion in 2025 and is projected to reach USD 18.58 billion by 2033, growing at a CAGR of 9.11% from 2026 to 2033. The rising global burden of cancer primarily drives market growth, the growing adoption of precision oncology, and continuous advancements in tissue-based diagnostic technologies.

Global Tissue Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global tissue diagnostics market report based on technology, modality, application, end use, and region:

  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Immunohistochemistry
    • Instruments
    • Slide Staining Systems
    • Tissue Microarrays
    • Tissue Processing Systems
    • Slide Scanners
    • Cell Processors
    • Microtomes
    • Embedding Systems
    • Cover Slippers
    • Other Products
    • Consumables
    • H&E stainer coverslipper
    • IHC stainer coverslipper
    • Antibodies
    • Other IHC reagents
  • In Situ Hybridization
    • Instruments
    • Stainers
    • Others
    • Total
    • Consumables
    • Software
  • Primary & Special Staining
  • Digital Pathology And Workflow
    • Image Analysis Informatics
    • Information Management System Storage & Communication
  • Anatomic Pathology
    • Instruments
    • Microtomes & Cryostat Microtomes
    • Tissue Processors
    • Automatic Strainers
    • Other Products
    • Consumables
    • Reagents & Antibodies
    • Probes & Kits
    • Others
  • Molecular Pathology
    • Instruments
    • Reagents
    • Fluorescence Reagents
    • Others
    • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Breast Cancer
  • Non-small Cell Lung Cancer
  • Prostate Cancer
  • Gastric Cancer
  • Other Cancers
  • Modality Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical market
  • Pharma / CRO / Research market
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic Center
  • Pharmaceutical Organizations
  • Contract Research Organizations (CROs)
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • Spain
    • France
    • Italy
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Application Segment
      • 1.1.1.2. Technology Segment
      • 1.1.1.3. Modality Segment
      • 1.1.1.4. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
    • 1.3.1. Objectives
    • 1.3.2. Objective - 1
    • 1.3.3. Objective - 2
    • 1.3.4. Objective - 3
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information or Data Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Technology & Application Snapshot
  • 2.3. Modality & End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Worldwide increase in cancer prevalence
      • 3.2.1.2. Advancements in imaging techniques and increasing affordability of diagnostics
      • 3.2.1.3. Growth of personalized therapeutics and diagnostics
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High costs associated with R&D and clinical trials
      • 3.2.2.2. Presence of non-value-based reimbursement policy
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis

Chapter 4. Technology Business Analysis

  • 4.1. Tissue Diagnostics Market: Technology Movement Analysis
  • 4.2. Immunohistochemistry
    • 4.2.1. Immunohistochemistry Market, 2021 - 2033 (USD Million)
    • 4.2.2. Instruments
      • 4.2.2.1. Instruments Market, 2021 - 2033 (USD Million)
      • 4.2.2.2. Slide Staining Systems
        • 4.2.2.2.1. Slide Staining Systems Market, 2021 - 2033 (USD Million)
      • 4.2.2.3. Tissue Microarrays
        • 4.2.2.3.1. Tissue Microarrays Market, 2021 - 2033 (USD Million)
      • 4.2.2.4. Tissue Processing Systems
        • 4.2.2.4.1. Tissue Processing Systems Market, 2021 - 2033 (USD Million)
      • 4.2.2.5. Slide Scanners
        • 4.2.2.5.1. Slide Scanners Market, 2021 - 2033 (USD Million)
      • 4.2.2.6. Cell Processors
        • 4.2.2.6.1. Cell Processors Market, 2021 - 2033 (USD Million)
      • 4.2.2.7. Microtomes
        • 4.2.2.7.1. Microtomes Market, 2021 - 2033 (USD Million)
      • 4.2.2.8. Embedding Systems
        • 4.2.2.8.1. Embedding Systems Market, 2021 - 2033 (USD Million)
      • 4.2.2.9. Cover Slippers
        • 4.2.2.9.1. Cover Slippers Market, 2021 - 2033 (USD Million)
      • 4.2.2.10. Other Products
        • 4.2.2.10.1. Other Products Market, 2021 - 2033 (USD Million)
    • 4.2.3. Consumables
      • 4.2.3.1. Consumables Market, 2021 - 2033 (USD Million)
      • 4.2.3.2. H&E stainer coverslipper
        • 4.2.3.2.1. H&E Stainer Coverslipper Market, 2021 - 2033 (USD Million)
      • 4.2.3.3. IHC stainer coverslipper
        • 4.2.3.3.1. IHC Stainer Coverslipper Market, 2021 - 2033 (USD Million)
      • 4.2.3.4. Antibodies
        • 4.2.3.4.1. Antibodies Market, 2021 - 2033 (USD Million)
      • 4.2.3.5. Others
        • 4.2.3.5.1. Others Market, 2021 - 2033 (USD Million)
  • 4.3. In situ Hybridization
    • 4.3.1. In situ Hybridization Market, 2021 - 2033 (USD Million)
    • 4.3.2. Instruments
      • 4.3.2.1. Instruments Market, 2021 - 2033 (USD Million)
      • 4.3.2.2. Stainers
        • 4.3.2.2.1. Stainers Market, 2021 - 2033 (USD Million)
      • 4.3.2.3. Others
        • 4.3.2.3.1. Others Market, 2021 - 2033 (USD Million)
      • 4.3.2.4. Total
        • 4.3.2.4.1. Total Market, 2021 - 2033 (USD Million)
    • 4.3.3. Consumables
      • 4.3.3.1. Consumables Market, 2021 - 2033 (USD Million)
    • 4.3.4. Software
      • 4.3.4.1. Software Market, 2021 - 2033 (USD Million)
  • 4.4. Primary & Special Staining
    • 4.4.1. Primary & Special Staining Market, 2021 - 2033 (USD Million)
  • 4.5. Digital Pathology & Workflow
    • 4.5.1. Digital Pathology & Workflow Market, 2021 - 2033 (USD Million)
    • 4.5.2. Image Analysis Informatics
      • 4.5.2.1. Image Analysis Informatics Market, 2021 - 2033 (USD Million)
    • 4.5.3. Information Management System Storage & Communication
      • 4.5.3.1. Information Management System Storage & Communication Market, 2021 - 2033 (USD Million)
  • 4.6. Anatomic Pathology
    • 4.6.1. Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 4.6.2. Instruments
      • 4.6.2.1. Instruments Market, 2021 - 2033 (USD Million)
      • 4.6.2.2. Microtomes & Cryostat Microtomes
        • 4.6.2.2.1. Microtomes & Cryostat Microtomes Market, 2021 - 2033 (USD Million)
      • 4.6.2.3. Tissue Processors
        • 4.6.2.3.1. Tissue Processors Market, 2021 - 2033 (USD Million)
      • 4.6.2.4. Automatic Strainers
        • 4.6.2.4.1. Automatic Strainers Market, 2021 - 2033 (USD Million)
      • 4.6.2.5. Other Products
        • 4.6.2.5.1. Other Products Market, 2021 - 2033 (USD Million)
    • 4.6.3. Consumables
      • 4.6.3.1. Consumables Market, 2021 - 2033 (USD Million)
      • 4.6.3.2. Reagents & Antibodies
        • 4.6.3.2.1. Antibodies & Reagents Market, 2021 - 2033 (USD Million)
      • 4.6.3.3. Probes & Kits
        • 4.6.3.3.1. Probes & Kits Market, 2021 - 2033 (USD Million)
      • 4.6.3.4. Others
        • 4.6.3.4.1. Others Market, 2021 - 2033 (USD Million)
  • 4.7. Molecular Pathology
    • 4.7.1. Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 4.7.2. Instruments
      • 4.7.2.1. Instruments Market, 2021 - 2033 (USD Million)
    • 4.7.3. Reagents
      • 4.7.3.1. Reagents Market, 2021 - 2033 (USD Million)
      • 4.7.3.2. Fluorescence Reagents
        • 4.7.3.2.1. Fluorescence Reagents Market, 2021 - 2033 (USD Million)
      • 4.7.3.3. Others
        • 4.7.3.3.1. Others Market, 2021 - 2033 (USD Million)
    • 4.7.4. Others
      • 4.7.4.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Tissue Diagnostics Market: Application Movement Analysis
  • 5.2. Breast Cancer
    • 5.2.1. Breast Cancer Market, 2021 - 2033 (USD Million)
  • 5.3. Non-Small Cell Lung Cancer
    • 5.3.1. Non-Small Cell Lung Cancer Market, 2021 - 2033 (USD Million)
  • 5.4. Prostate Cancer
    • 5.4.1. Prostate Cancer Market, 2021 - 2033 (USD Million)
  • 5.5. Gastric Cancer
    • 5.5.1. Gastric Cancer Market, 2021 - 2033 (USD Million)
  • 5.6. Other Cancers
    • 5.6.1. Other Cancers Technology Market, 2021 - 2033 (USD Million)

Chapter 6. Modality Business Analysis

  • 6.1. Tissue Diagnostics Market: Modality Movement Analysis
  • 6.2. Clinical
    • 6.2.1. Clinical Market, 2021 - 2033 (USD Million)
  • 6.3. Pharma / CRO / Research market
    • 6.3.1. Pharma / CRO / Research Market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

  • 7.1. Hospitals
    • 7.1.1. Hospitals Market, 2021 - 2033 (USD Million)
  • 7.2. Diagnostic Center
    • 7.2.1. Diagnostic Center Market, 2021 - 2033 (USD Million)
  • 7.3. Pharmaceutical Organizations
    • 7.3.1. Pharmaceutical Organizations Market, 2021 - 2033 (USD Million)
  • 7.4. CRO
    • 7.4.1. CRO Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Tissue Diagnostics Market Share By Region, 2025 & 2033
  • 8.2. North America
    • 8.2.1. SWOT Analysis
    • 8.2.2. North America Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.3. U.S.
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. U.S. Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Mexico Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.5. Canada
      • 8.2.5.1. Key Country Dynamics
      • 8.2.5.2. Target Disease Prevalence
      • 8.2.5.3. Competitive Scenario
      • 8.2.5.4. Regulatory Framework
      • 8.2.5.5. Canada Tissue Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.3. Europe
    • 8.3.1. SWOT Analysis
    • 8.3.2. Europe Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. UK Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.4. Germany
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Germany Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.5. Spain
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Spain Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.6. France
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. France Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.7. Italy
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Italy Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.8. Denmark
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Denmark Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.9. Sweden
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Sweden Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.10. Norway
      • 8.3.10.1. Key Country Dynamics
      • 8.3.10.2. Target Disease Prevalence
      • 8.3.10.3. Competitive Scenario
      • 8.3.10.4. Regulatory Framework
      • 8.3.10.5. Norway Tissue Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. SWOT Analysis
    • 8.4.2. Asia Pacific Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.3. Japan
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Japan Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.4. China
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. China Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.5. India
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. India Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. South Korea Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.7. Australia
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Australia Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.8. Thailand
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Target Disease Prevalence
      • 8.4.8.3. Competitive Scenario
      • 8.4.8.4. Regulatory Framework
      • 8.4.8.5. Thailand Tissue Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.5. Latin America
    • 8.5.1. SWOT Analysis
    • 8.5.2. Latin America Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.3. Brazil
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Brazil Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Competitive Scenario
      • 8.5.4.4. Regulatory Framework
      • 8.5.4.5. Argentina Tissue Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.6. MEA
    • 8.6.1. SWOT Analysis
    • 8.6.2. MEA Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.3. South Africa
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. South Africa Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. UAE Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.5. Saudi Arabia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Saudi Arabia Tissue Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.6. Kuwait
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Competitive Scenario
      • 8.6.6.4. Regulatory Framework
      • 8.6.6.5. Kuwait Tissue Diagnostics Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Share Analysis, 2025
  • 9.4. Company Profiles/Listing
    • 9.4.1. F. Hoffmann-La Roche Ltd.
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.1.3. Technology Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Abbott Laboratories
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.2.3. Technology Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Thermo Fisher Scientific, Inc.
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.3.3. Technology Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Siemens
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.4.3. Technology Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. Danaher Corporation
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.5.3. Technology Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. bioMerieux SA
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.6.3. Technology Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. QIAGEN
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.7.3. Technology Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. BD
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.8.3. Technology Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Merck KGaA
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.9.3. Technology Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. GE Healthcare
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.10.3. Technology Benchmarking
      • 9.4.10.4. Strategic Initiatives
    • 9.4.11. BioGenex
      • 9.4.11.1. Overview
      • 9.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.11.3. Technology Benchmarking
      • 9.4.11.4. Strategic Initiatives
    • 9.4.12. Cell Signaling Technology, Inc.
      • 9.4.12.1. Overview
      • 9.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.12.3. Technology Benchmarking
      • 9.4.12.4. Strategic Initiatives
    • 9.4.13. Bio SB
      • 9.4.13.1. Overview
      • 9.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.13.3. Technology Benchmarking
      • 9.4.13.4. Strategic Initiatives
    • 9.4.14. DiaGenic ASA
      • 9.4.14.1. Overview
      • 9.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.14.3. Technology Benchmarking
      • 9.4.14.4. Strategic Initiatives
    • 9.4.15. Agilent Technologies, Inc
      • 9.4.15.1. Overview
      • 9.4.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.15.3. Technology Benchmarking
      • 9.4.15.4. Strategic Initiatives
×

원하시는 정보를 찾아 드릴까요?

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기